Merck’s HIV drug doravirine looks solid — though far less stellar than rivals — in 1st PhIII
Merck’s late-stage antiviral doravirine (MK-1439) came through in its first Phase III study, matching up nicely against J&J’s blockbuster Prezista.
The non-nucleoside reverse transcriptase inhibitor compared closely to the rival therapy in the non-inferiority test, adding a positive secondary endpoint on lower LDL levels among patients. The drug used in a cocktail remedy eliminated all signs of the virus among 83.8% (321/383) compared to 79.9% for Prezista (306/383).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
